comprehensive -WSS

comprehensive

author：entertainment 2025-09-30 17:28:57 - browse：23873

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： What nurses really want: sufficient staffing for patient care

entertainment

WSS

Health and fitness trackers are measuring the wrong things

The SUPPORT Act is critical to fighting the opioid crisis

Shionogi licenses Pompe disease therapy from Maze Therapeutics

The nurse manager staffing crisis is hurting patients

H5N1 communication has been strictly for the birds

The SUPPORT Act is critical to fighting the opioid crisis

leisure time

comprehensive

hotspot

Medical leaders decry Supreme Court decision on affirmative action

How to improve immunocompromised access to mAb treatments

Medicare proposal to cover medical devices draws a mixed reaction

CDC wastewater surveillance dashboard to track bird flu hotspots

Affirmative action in medical school literally saved lives

GSK to buy asthma

As demand for Covid shots wanes, Moderna seeks its next success

The nurse manager staffing crisis is hurting patients

The cancer drug shortage isn’t new — and neither are the solutions

Bird flu outbreak in cows is latest avian flu curveball

explore

Biotech reporter’s notebook: A sunnier mood at JPM 2024

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

Generative AI mines health records to identify patients’ social needs

H5N1 communication has been strictly for the birds

Study: People of West African ancestry at greater risk of cardiac amyloidosis

Readout LOUD podcast: What to know about H5N1 bird flu

focus

entertainment

entertainment

explore